Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: DXCM

DexCom, Inc.

Healthcare | Medical - Devices

Market prices for DXCM are shown to signed-in users (sign in). This public page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$2.52

DexCom, Inc. (NASDAQ: DXCM) is a medical device company. Figures from SEC EDGAR; updated 2026-10-20 05:59 UTC.

What DexCom, Inc. does

This company manufactures medical devices, including continuous glucose monitoring systems, that are subject to FDA regulatory oversight. Before marketing devices, the company must obtain FDA authorization through processes like the 510(k) clearance pathway. After a device reaches the market, the company must comply with extensive requirements including facility registration, quality management systems, labeling restrictions, adverse event reporting to the FDA, and product recalls when necessary.

Summarized from DexCom, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$2.52
Return on equity30.46%

Revenue, margins & earnings

FY2021 Net income: $217MFY2021 Taxes & interest: $49MFY2021 Operating expenses: $1.41BFY2021 Cost of revenue: $768M$2.45BFY2021FY2022 Net income: $341MFY2022 Taxes & interest: $50MFY2022 Operating expenses: $1.49BFY2022 Cost of revenue: $1.03B$2.91BFY2022FY2023 Net income: $542MFY2023 Taxes & interest: $56MFY2023 Operating expenses: $1.69BFY2023 Cost of revenue: $1.33B$3.62BFY2023FY2024 Net income: $576MFY2024 Operating expenses: $1.84BFY2024 Cost of revenue: $1.59B$4.03BFY2024FY2025 Net income: $836MFY2025 Taxes & interest: $76MFY2025 Operating expenses: $1.89BFY2025 Cost of revenue: $1.86B$4.66BFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-30
  • 2026-09-30EVP Chief People & Culture OffSale-2,565$221.0K
  • 2026-09-16DirectorSale-1,550$130.2K
  • 2026-09-16EVP Chief Legal Compliance OffSale-1,700$142.9K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does DexCom, Inc. do?

This company manufactures medical devices, including continuous glucose monitoring systems, that are subject to FDA regulatory oversight.

When did DXCM last file with the SEC?

DexCom, Inc.'s most recent SEC filing on record is a 10-Q filed 2026-07-30. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 05:59 UTC. This page is also available as JSON at /api/data?ticker=DXCM and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for DXCM and 5,000+ tickers.

Create a free account — keep DXCM
For your agent
GET /api/data?ticker=DXCM

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt